Pharmacoeconomics
-
Publication Venue For
- Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care.. 34:273-284. 2016
- Cost-Effectiveness Analysis of Qsymia for Weight Loss.. 33:699-706. 2015
- Challenges in merging Medicaid and Medicare databases to obtain healthcare costs for dual-eligible beneficiaries: using diabetes as an example.. 27:167-177. 2009
- Economic burden of heart failure in the elderly.. 26:447-462. 2008
- Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.. 26:435-446. 2008
- Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. 25:343-351. 2007
- Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.. 24:479-494. 2006
- Impact of Medicaid preferred drug lists on therapeutic adherence.. 24 Suppl 3:65-78. 2006
- Price differentiation and transparency in the global pharmaceutical marketplace.. 23:651-658. 2005
- The impact of anaemia and its treatment on employee disability and medical costs.. 23:183-192. 2005
- The economic burden of allergic rhinitis: a critical evaluation of the literature.. 22:345-361. 2004
- Cost effectiveness of abciximab during routine medical practice.. 18:265-274. 2000
- Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome.. 17:263-272. 2000
- The distribution of sales revenues from pharmaceutical innovation.. 18 Suppl 1:21-32. 2000
- Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.. 16:459-472. 1999
- Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications.. 15:257-268. 1999
- Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.. 15:141-155. 1999
- Treating myocardial infarction in the post-GUSTO era. A US perspective.. 9:473-477. 1996
- Cost of treatment and prevention of Haemophilus influenzae type b disease. An international perspective.. 6:442-452. 1994
- The effect of Medicaid formularies on the availability of new drugs.. 1:32-40. 1992